BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38736552)

  • 1. Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model.
    Yang H; Ruan Y; Sun Y; Wang P; Qiao J; Wang C; Liu Z
    Ther Adv Med Oncol; 2024; 16():17588359241249578. PubMed ID: 38736552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 3. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
    Zhu M; Liang C; Zhang F; Zhu L; Chen D
    Front Oncol; 2021; 11():690336. PubMed ID: 34745934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K).
    Han R; Ma Y; Liu Z; Li C; Li S; Kong X; Han M; Liu Y; Geng C
    Transl Breast Cancer Res; 2022; 3():24. PubMed ID: 38751546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.
    Lai J; Wang H; Peng J; Chen P; Pan Z
    Cancer Manag Res; 2018; 10():2347-2356. PubMed ID: 30122984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study.
    Wang MD; Duan FF; Hua X; Cao L; Xia W; Chen JY
    Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():831848. PubMed ID: 35320931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis.
    Maimaitiaili A; Fan Z; Zhang J; Wang Y; Shi B; Zheng J; Li G; Zhao Y; Pu S; He J; Qu F; Zhang H
    Ther Adv Med Oncol; 2024; 16():17588359241248318. PubMed ID: 38716480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy.
    Hou N; Wu J; Xiao J; Wang Z; Song Z; Ke Z; Wang R; Wei M; Xu M; Wei J; Qian X; Xu X; Yi J; Wang T; Zhang J; Li N; Fan J; Hou G; Wang Y; Wang Z; Ling R
    ESMO Open; 2021 Oct; 6(5):100269. PubMed ID: 34537675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomograms for Predicting Disease-Free Survival Based on Core Needle Biopsy and Surgical Specimens in Female Breast Cancer Patients with Non-Pathological Complete Response to Neoadjuvant Chemotherapy.
    Lan A; Li H; Chen J; Shen M; Jin Y; Dai Y; Jiang L; Dai X; Peng Y; Liu S
    J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy.
    Wang W; Wang X; Liu J; Zhu Q; Wang X; Wang P
    Chin Med J (Engl); 2021 Dec; 135(3):333-340. PubMed ID: 35108228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy.
    Lai J; Pan Z; Chen P; Ye G; Chen K; Su F
    Jpn J Clin Oncol; 2019 Jan; 49(1):22-28. PubMed ID: 30508184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
    Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
    Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
    Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():849468. PubMed ID: 35669769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.
    Kim JY; Park HS; Kim S; Ryu J; Park S; Kim SI
    Medicine (Baltimore); 2015 Oct; 94(43):e1720. PubMed ID: 26512562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.